This is the September edition of our spinout tracker (you can access previous months here). The list is updated weekly throughout the month.
We welcome submissions from tech transfer offices with information on their latest spinouts.
If you would like one of your portfolio companies considered for inclusion in a future list, please send us an email. Eligible companies must be early-stage. However, they need not have raised capital yet and can use this list to advertise that they are open to investors.
| Added | Company | University | Location | Sector | Technology | Round | Amount ($m) | Investors | Amount ($m) |
|---|---|---|---|---|---|---|---|---|---|
| 09/06/2024 | Lucid Genomics | Charite University Hospital | Germany | Health | AI-digital health platform that extracts genomic information to improve diagnostics and drug discovery | Pre-seed | 1.45 | Caesar Ventures; BIF Partners; another.vc; MPF Accelerator | $0 – $5m |
| 09/06/2024 | Oxylus Energy | Yale University | US | Cleantech | carbon utilisation technology for the production of green fuels and chemical feedstocks | Seed | 4.5 | Toyota Ventures; Azolla Ventures; Earth Foundry; Connecticut Innovations | $0 – $5m |
| 09/06/2024 | Infinigence AI | Tsinghua University | China | Information Technology | developer of hardware to optimise large language model training and inference | Series A | 70.2 | Qiming Venture Partners; Hongtai Aplus; Lenovo Capital & Incubator Group; Xiaomi Corp. | $70.1m – $75m |
| 6/9//2024 | HDAX | University of Toronto | Canada | Health | molecular recognition technology for the treatment of disease | Seed | 3.2 | SeedFolio; FACIT; Toronto Innovation Acceleration Partners; Eos Bioinnovation; Ontario Centre of Innovation | $0 – $5m |
| 09/06/2024 | Mantel | Massachussetts Institute of Technology | US | Cleantech | developer of molten-salt-based carbon capture technology | Series A | 30 | Shell Ventures; Eni Next; Engine Ventures; New Climate Ventures; Hartree; bp Ventures; Arosa Ventures; Yale Ventures; Newlab; MCJ Collective | $25.1m – $30m |
| 09/06/2024 | Ellethermo | Tokyo Institute of Technology | Japan | Information Technology | semiconductor-sensitised thermal cell developer | Pre-series A | 2.5 | Hulic; KDDI Green Partners Fund; Keio Innovation Initiative; Mirai Souzo; Mitsubishi UFJ Capital; Mizuho Capital | $0 – $5m |
| 09/06/2024 | Awen Oncology | Bangor University; Cardiff University | UK | Health | developer of oncology treatments taht target specific proteins in cancer cells | Undisclosed | Undisclosed | Development Bank of Wales; Start Codon | Undisclosed |
| 09/06/2024 | ScubaTx | Newcastle University | UK | Health | developer of organ transplant technology | Undisclosed | 1.8 | Praetura Ventures | $0 – $5m |
| 09/06/2024 | Mindgard | Lancaster University | UK | Information Technology | AI security platform | Seed | 4 | IQ Capital; Lakestar | $0 – $5m |
| 13/09/2024 | CardiaTec | University of Cambridge | UK | Health | AI-driven platform that uses multiomics data to find therapeutics for cardiovascular disease | Seed | 6.5 | Montage Ventures; Continuum Health Ventures, Laidlaw Ventures, Apex Ventures | $5.1m – $10m |
| 13/09/2024 | Brightflow | Université Paris-Est Créteil | France | Health | developer of a medical device to support treatment of right ventricular heart failure | Series A | 18 | VIVES Partners; UI Investissement; BNP Paribas Development | $15.1m – $20m |
| 13/09/2024 | Myostellar | Monash University | Australia | Health | developer of therapeutics for skeletal muscle regeneration | Undisclosed | 0.34 | Brandon Capital | $0 – $5m |
| 13/09/2024 | GILZrx | Monash University | Australia | Health | novel drug alternative to glucocorticoids in the treatment of inflammatory and autoimmune diseases | Undisclosed | 0.34 | Brandon Capital | $0 – $5m |
| 13/09/2024 | Exergy3 | University of Edinbriugh | UK | Cleantech | high temperature thermal energy storage technology | Pre-seed | 1.3 | Zero Carbon Capital | $0 – $5m |
| 13/09/2024 | Allogenetics | Medical School Hanover | Germany | Health | deveoloper of an alternative to immunosuppressants to prevent organ failure in transplants | Seed | 3.7 | NBank Capital; Carma Fund I | $0 – $5m |
